Vir Biotechnology, Inc. (VIR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '24: 78.6M Q4 '24: 74.2M Q1 '25: 20.9M Q2 '25: 19M Q3 '25: 16.9M Q4 '25: 68.6M Q1 '26: 65.5M Q2 '26: 303.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 40M 80M 120M Q3 '23: 110.8M Q4 '23: 83.4M Q1 '24: 78.7M Q2 '24: 77.9M Q3 '24: 77.7M Q4 '24: 73.4M Q1 '25: 20.1M Q2 '25: 18.3M Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '24: -609M Q4 '24: -587.2M Q1 '25: -646.6M Q2 '25: -606.4M Q3 '25: -548.6M Q4 '25: -479.3M Q1 '26: -472.1M Q2 '26: -280.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -533.3M Q4 '24: -522M Q1 '25: -577.6M Q2 '25: -550.2M Q3 '25: -499.7M Q4 '25: -438M Q1 '26: -442.7M Q2 '26: -251.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 3M 6M 9M Q3 '23: 8M Q4 '23: 2.8M Q1 '24: 917K Q2 '24: 947K Q3 '24: 959K Q4 '24: 845K Q1 '25: 786K Q2 '25: 745K Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -466.6M Q4 '24: -446.4M Q1 '25: -415.1M Q2 '25: -457.4M Q3 '25: -453.5M Q4 '25: -391.8M Q1 '26: -446.1M Q2 '26: -202.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -473.5M Q4 '24: -453.7M Q1 '25: -422.1M Q2 '25: -466.4M Q3 '25: -460M Q4 '25: -396.6M Q1 '26: -449.6M Q2 '26: -203.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q1 '24: 135.3M Q2 '24: 136.2M Q3 '24: 136.7M Q1 '25: 137.5M Q2 '25: 138.4M Q3 '25: 138.9M Q1 '26: 147.4M Q2 '26: 168.9M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '24: -3.92 Q4 '24: -3.82 Q1 '25: -4.22 Q2 '25: -4.00 Q3 '25: -3.61 Q4 '25: -3.15 Q1 '26: -3.12 Q2 '26: -1.85 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.